The FDA has granted fast track designation to MWTX-003 for the treatment of patients with polycythemia vera.
The FDA has granted fast track designation to MWTX-003 (also DISC-3405) for the treatment of patients with polycythemia vera (PV).1
MWTX-003 is an investigational anti-TMPRSS6 monoclonal antibody. The drug is designed to inflate hepcidin production and suppress serum iron. In preclinical studies, MWTX-003 treatment led to increased hepcidin production and suppression of serum iron levels in beta-thalassemia and polycythemia vera animal models.
Following an investigational new drug application being cleared by the FDA in November of 2022, MWTX-003 is now being investigated in a phase 1 clinical trial.
“We are delighted to have received fast track designation for MWTX-003, which highlights the unmet need for PV patients and the potential of MWTX-003 in a disease where there are few treatment options,” said John Quisel, JD, PhD, president and chief executive officer of Disc, in a press release. “We believe MWTX-003 is uniquely positioned to address the needs of PV patients and are excited to initiate a phase 1 trial in the coming months.”
MWTX-003 has no regulatory approval for any indication worldwide. Disc Medicine, Inc, plans to develop MWTX-003 in PV, as well as in other hematologic malignancies.
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Scott Evaluates Treatment Options for Hydroxyurea-Resistant Polycythemia Vera
March 28th 2024In a Community Case Forum event in partnership with the Washington State Medical Oncology Society, Bart Scott, MD, broke down various trials of hydroxyurea, ruxolitinib, and interferon in patients with polycythemia vera to assess outcomes such as hematocrit control and molecular response.
Read More